Dexmedetomidine ameliorates high-fat diet-induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice

Linfen Tao1,2 | Xiaolong Guo3 | Min Xu1 | Yumeng Wang1 | Wenhua Xie1
Hong Chen1 | Mengyao Ma1 | Xi Li1

Abstract
Fatty liver disease is one of the main hepatic complications associated with obesity. To date, there are no therapeutic drugs approved for this pathology. Insulin resistance (IR) is implicated both in pathogenesis of nonalcoholic fatty liver disease (NAFLD) and in disease progression from steatosis to nonalcoholic steatohepatitis. In this study, we have characterized effects of an α2-adrenoceptor agonist, dexmedetomidine (DEX), which can alleviate IR in hepatocytes in high-fat diet (HFD)-induced NAFLD mice. The NAFLD mice received a daily intraperitoneal administration of DEX (100 μg·kg−1) after 16 days exhibited lower body weight, fewer and smaller fat droplets in the liver, markedly reduced the plasma triglyceride levels, accompanied by improvement of liver damage. This inhibition of lipid accumulation activity in obese mice was associated with a robust reduction in the mRNA and protein expression of the lipogenic enzyme stearyl-coenzyme A desaturase 1 (SCD1), which was probably mediated by the inhibition of C/EBP β, PPAR γ and C/EBP α through suppressing α2A-adrenoceptor (α2A-AR) via negative feedback. Additionally, DEX can also improve IR and inflammation by inhibiting the mitogen-activated protein kinases (MAPK) and nuclear factor kappa beta (NFκB) signaling pathway in vivo. Our findings implicate that DEX may act as a potential anti-steatotic drug which ameliorates obesity-associated fatty liver and improves IR and inflammation, probably by suppressing the expression of SCD1 and the inhibition of MAPK/NFκB pathway and suggest the potential adjuvant use for the treatment of NAFLD.

KEYWORDS
DEX, NAFLD, SCD1, α2A-AR

Acknowledgements: ALT, alanine transaminase; AST, aspartate transaminase; C/EBP, CCAAT enhancer-binding protein; DEX, Dexmedetomidine; H&E, hematoxylin and eosin; HDL-C, high-density lipoprotein cholesterol; HFD, high-fat diet; IpGTT, Intraperitoneal Glucose Tolerance Test; IpITT, Intraperitoneal Insulin Tolerance Test; IR, insulin resistance; MAPK, mitogen-activated protein kinases; NAFLD, Nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NFκB, nuclear factor kappa beta; ORO, Oil Red O; PPAR γ, peroxisome proliferators-activated receptor γ; SCD1, stearyl-coenzyme A desaturase 1; T-CHO, total cholesterol; α2A-AR, α2A-adrenoceptor.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
1 | INTRODUCTION

NAFLD has significantly increased in prevalence in parallel with increasing obesity and is now the most common cause of chronic liver disease in the worldwide.1 NAFLD begins with accumulation of triacylglycerols in the liver (steatosis), and is defined by hepatic fatty infiltration amounting to greater than 5% by liver weight or the presence of over 5% of hepatocytes loaded with large fat vacuoles.2-3 This disease is heterogeneous and represents a spectrum of diseases ranging from simple steatosis to more severe forms of liver injury including nonalcoholic steatohepatitis, fibrosis, and hepatocellular carcinoma.4-6 Current management of NAFLD7 is largely focused on lifestyle interventions through diet and exercise to try and achieve weight loss and to ameliorate underlying metabolic and cardiovascular risk factors.8-10 Although many pharmacological interventions, including antidiabetic agents, antidiyslipidemic drugs, antihypertensive drugs, antiobesity drugs, and several other treatment targets, to limit the development and progression of NAFLD have been tested,7 none are to date specifically licensed for the treatment of NAFLD and efforts to control complications arising from the condition are far from satisfactory. Thus, better understanding of hepatocytic lipid accumulation and inflammation might provide a new therapeutic strategy for NAFLD prevention and treatment.

NAFLD is closely associated with IR and type 2 diabetes,11 IR is implicated both in pathogenesis of NAFLD and in disease progression from steatosis to NASH.12 Thus, modulation of IR represents a potential strategy for NAFLD treatment. It has been recently reported that DEX can alleviate IR in hepatocytes13 by reducing endoplasmic reticulum stress and protect against hepatic lipid peroxidation and histological damage in sepsis and IR animal models.14-16 In addition, studies have found that DEX can maintain postoperative blood glucose stability17 and reduce blood glucose level in diabetic patients by inhibiting systemic inflammation. These all suggest that DEX may play a protective role in body metabolic homeostasis. Based on these findings, we speculated that DEX can act against HFD-induced obesity and NAFLD and the underlying molecular mechanism deserves further study.

DEX is a highly selective α2-adrenoceptor (α2-AR) and imidazoline receptor agonist,18 has been widely used for sedation and analgesia in anesthesia as well as antihypertensive, anxiolytic, and anti-delirium in the intensive care unit.19-21 DEX can exert its effects via activation of three α2-adrenoceptor subtypes: α2A and α2C-adrenoceptor (α2A-AR and α2C-AR) located in presynaptic membrane, and regulate the release of neurotransmitter (noradrenaline) in the central nervous system (CNS), cause transient hypertension, hyperglycemia, and tachycardia, which form a negative feedback loop to reduce the release of norepinephrine by inhibiting α2A-AR.22 Studies have been reported that stimulation of α2A-AR can activate cyclic AMP-response element-binding protein (CREB)23; depletion of CREB inhibits the expression of C/EBP α, C/EBP β, and PPAR γ.24 Besides, SCD1 is one of the down-stream genes of PPAR γ25 and the transcription of PPAR γ can be activated by C/EBP β and C/EBP α.26

In this study, we demonstrated that DEX ameliorates HFD-induced NAFLD by targeting SCD1 via negative feedback in obesity mice, explore the signaling pathway involved and to identify a novel function of DEX on limiting fat accumulation in liver.

2 | MATERIALS AND METHODS

2.1 | Animals and treatments

All experimental procedures and the protocols with animals were approved by the Animal Care and Use Committee of the Chongqing Medical University and followed the National Institute of Health guidelines on the care and use of animals. The experiments were performed on 6- to 8-week-old male C57BL/6J. The mice were purchased from the Experimental Animal Center of Chongqing Medical University (Chongqing, China) and group-housed (5 mice per cage) 12-hour light/12-hour dark cycles, fed with normal diet (ND) and HFD (60% kcal in fat, beginning at age 8 week) and provided water ad libitum. IpGTT and IpITT were performed at 22-23 weeks of age to evaluate the whole-body metabolic state and insulin sensitivity, and then mice fed with HFD were assigned randomly to either the treatment group or control group based on bodyweight. DEX (Jiangsu Hengrui pharmaceutical co. LTD, China) was dissolved in saline which as a Vehicle at a terminal concentration of 20 ng·μL-1 and injected intraperitoneally (i.p.) at a dose of 100 μg per kg body weight (μg·kg-1), the rationale for DEX dosage and concentration selections were mainly referred to some other previous research reports.27-30 Animals received a daily i.p. injection of Vehicle or DEX for 16 consecutive days. Ten mice per group were used for the experiment. Food intake (in grams) and body weight (in grams) were monitored daily (Figure 1A).

2.2 | Biochemical analysis in plasma

The following metabolites and metabolic hormones were measured in plasma: aspartate transaminase (AST), alanine transaminase (ALT), total cholesterol (T-CHO), high-density lipoprotein cholesterol (HDL-C) assay kits were obtained from Jiancheng Institute of Biotechnology (Nanjing, China). Plasma insulin assay kit was purchased fromCUSABIO (Wuhan, China) according to the manufacturer’s instructions.

2.3 | Histological analysis of tissues

Liver samples were fixed in 4% paraformaldehyde and embedded in paraffin for histological assessments with hematoxylin and eosin (H&E) staining. Cryostat frozen sections were stained with...
FIGURE 1  DEX protects mice against HFD-induced NAFLD. (A) Schematic shows the DEX and Vehicle injection strategy used in this study. In short, the mice were group-housed (5 mice per cage) and fed with HFD (beginning at age 8 week). IpGTT and IpITT were carried out after 14 weeks of ND or HFD feeding. At 22–23 weeks of age, HFD fed mice were assigned randomly to treatment and control group based on bodyweight. DEX was dissolved in saline which as a Vehicle at a terminal concentration of 20 ng μL⁻¹ and injected intraperitoneally (i.p.) at a dose of 100 μg per kg body weight (μg kg⁻¹). Animals received a daily i.p. injection of Vehicle or DEX for 16 consecutive days. Ten mice per group were used for the experiment. Food intake and body weight were monitored daily (n = 10 per group). (B) Body weight of mice when sacrificed (n = 10 per group); (C) Changes in body weight daily while injection; (D) food intake once every 2 days while injection; (E) plasma total cholesterol (T-CHO) concentrations when sacrificed (n = 7 per group); (F) plasma high-density lipoprotein cholesterol (H-DLC) concentrations when sacrificed (n = 7 per group); (G) and (H) liver weight and appearance when sacrificed, Representative images are shown; (I) H&E and ORO staining of liver when sacrificed, Scale bars, 50 μm and 20 μm; (J) and (K) plasma ALT and AST activities were analyzed 24 h after the last injection (n = 7 per group). Data were analyzed by unpaired two-tailed Student’s t-test. Values are expressed as the mean ± SD *P < .05; ** P < .01; *** P < .001
Oil Red O (ORO) staining for analysis of lipids and fat depots in the liver.

2.4 | RNA isolation and RT-QPCR analysis

Total RNA was extracted using Trizol Reagent (Invitrogen, USA) and quantified using a spectrophotometer to ensure ratios of absorbance at 260 to 280 nm of 1.8–2.0. RNA was reversed-transcribed to generate cDNA using the Revert Aid first-strand cDNA synthesis kit (Thermo Scientific, USA) as per manufacturer’s instructions. And then analyzed using the Power SYBR green PCR master mix (Applied Biosystems, Carlsbad, CA) with the ABI Prism 7500 qPCR machine (Applied Biosystems). Standard curves were constructed for each gene to confirm amplification efficiency. Quantification was calculated using the comparative cycle threshold ($2^{-\Delta\Delta Ct}$) method.

2.5 | Protein extraction and western blot analysis

Tissue homogenate or cell lysate in lysis buffer containing 10% SDS and 1 M Tris–HCl (pH 6.8) supplemented with a cocktail of protease inhibitors (cOmplete Tablets) and phosphatase inhibitors (Roche, Germany). Lysates were then quantitated and equal amounts of proteins were subjected to SDS-PAGE and immunobotted with antibodies against HSP 90, SCD1, p-P65/P65, p-P38/P38, p-JNK/JNK, PPAR γ, C/EBPα, C/EBP β, FASN, ACC. Antibodies against HSP 90, p-P65/ P65, p-P38/P38, p-JNK/JNK, and PPAR γ were from Cell Signaling Technology (Beverly, MA, USA), antibodies against C/EBP α was from Santa Cruz Biotechnology (Santa Cruz, CA, USA), antibodies against SCD1, FASN, and ACC were from proteintech (Wuhan, China), and antibodies against C/EBP β was from the Department of Biological Chemistry, Johns Hopkins University School of Medicine.

2.6 | Intraperitoneal glucose and insulin tolerance test (IPGTT/IPITT)

For the glucose tolerance test (GTT), mice were fasted for 14 h, weighed and basal blood samples were taken from the tail tip, followed by intraperitoneal glucose injection with a 25% glucose solution (1 mg/g body weight), and tail blood glucose levels were taken at 30, 60, 90, and 120 min. For the insulin tolerance test (ITT), mice fasted for 4 h, weighed and basal blood samples taken from the tail tip, followed by intraperitoneal human insulin injection (Novo Nordisk) (0.75mU/g body weight), and tail blood glucose levels taken at 15, 30, 45, and 60 min.

2.7 | Cell culture

Human hepatic carcinoma cell line HepG2 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, USA) containing 10% (vol/vol) fetal bovine serum (FBS; Biological Industries, Israel), 1% penicillin-streptomycin (Beyotime, China) at 37°C with humidified air and 5% CO$_2$. Primary hepatocytes were isolated from C57BL/6j mice and cultured in Dulbecco’s modified Eagle medium-low sugar (DMEM; Gibco, USA) with 10% fetal bovine serum (FBS; Biological Industries, Israel) for 2 to 4 h, after cells have attached, keep cells in serum-free medium to maintain their morphology.

2.8 | Statistical analysis

All the data in the graphs were expressed as mean ± standard deviations (SD). The statistical analysis was performed using GraphPad Prism version 8.0.1 (GraphPad Software). The significance of differences within and between groups was primarily evaluated using two-way analysis of variance [ANOVA; factors: treatment (Vehicle/DEX) or time] and the appropriate post hoc test for multiple comparisons. Comparisons between groups were made by unpaired two-tailed Student’s t-test, where $p < .05$ was considered as statistically significant.

2.9 | Nomenclature of Targets and Ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY,\textsuperscript{21} and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20.\textsuperscript{22}

3 | Results

3.1 | DEX protects mice against HFD-induced obesity and NAFLD

To investigate the effects of DEX on HFD-induced obesity and NAFLD, the obese mice fed HFD for 14 weeks were treated intraperitoneally with DEX or Vehicle. The changes in body weight and food intake were monitored daily. Interestingly, the treatment with DEX significantly reduced the body weight while food intake was less during the initial 7 days posttreatment but there was no significant difference after 7 days treatment (Figure 1B-D). Furthermore, the DEX group displayed lower levels of both total cholesterol (T-CHO) (Figure 1E) and high-density lipoprotein cholesterol (HDL-C) (Figure 1F) concentrations than controls. Consistent with these data, H&E histological and ORO staining (Figure 1I) showed that fat accumulation also decreased dramatically in livers of DEX-treated mice, accompany with decreasing liver weight (Figure 1G) and less pale liver(Figure 1H) comparing with Vehicle mice.

Furthermore, DEX-treated mice had significantly lower serum alanine transaminase (ALT) and aspartate transaminase (AST) activities (Figure 1J and K), indicating that DEX alleviated liver injury in HFD-induced NAFLD. These findings indicate that DEX may play a protective role in HFD-induced obesity and NAFLD.
3.2 DEX protects against HFD-induced hepatic glucose intolerance and improves insulin sensitivity

To assess whether fatty liver model is successful and to evaluate the whole-body metabolic state and insulin sensitivity before DEX treatment, IpGTT and IpITT were carried out after 14 weeks of ND or HFD feeding. The results showed significantly impaired glucose tolerance and markedly blunted insulin responsiveness in HFD-fed mice relative to ND-fed mice (Figure 2A and B). To test whether hepatic glucose metabolism could be modulated by DEX, IpGTT and IpITT were performed on mice at day 9 and day 13 after DEX treatment. We found that glucose intolerance (Figure 2C) and insulin resistance (Figure 2D) were improved with DEX treatment compared with Vehicle. Furthermore, DEX-treated mice had significantly lower random blood glucose levels compared with Vehicle (Figure 2E), suggests that DEX increased whole-body insulin sensitivity. In addition, we detected lipid infiltration in the liver using ORO staining prior and after DEX treatment, the liver exhibited fewer and smaller fat droplets in the liver after DEX treatment (Figure 2F). These findings suggest that DEX can protect against HFD-induced hepatic glucose intolerance and improves insulin sensitivity.

3.3 DEX impedes SCD1, C/EBP α, C/EBP β, AND PPAR γ

To identify the molecular mechanisms underlying the anti-steatotic role of DEX, the expression of key lipid metabolism genes were screened, including FA synthesis, TG synthesis, FA oxidation, and lipid uptake genes in liver. The data revealed that the mRNA expression of stearoyl-Coenzyme A desaturase 1 (SCD1), which catalyzes saturated fatty acids to form monounsaturated fatty acids was dramatically decreased in DEX-treated mice (Figure 3A). The protein level of SCD1 also decreased in DEX-treated mice compared to Vehicle mice (Figure 3B and D). These data suggest that DEX decrease lipogenic genes expression especially downregulate the expression of SCD1 in vivo. Then we detected the protein level of C/EBP β, C/EBP α, and PPAR γ, all of them were significantly decreased in DEX-treated mice compared to Vehicle mice (Figure 3C and D).

**FIGURE 2** DEX protects against HFD-induced glucose intolerance and improves insulin sensitivity. (A) and (B) IpGTT and IpITT were performed at 22–23 weeks of age among ND and HFD fed mice (n = 6 per group); (C) and (D) IpGTT and IpITT assays were conducted among DEX and Vehicle-injected mice (n = 10 per group); (C) For the IpGTT, mice began fasting at 7 PM on day 8 for 14 h, then weighed and basal blood samples taken from the tail tip at 9 AM on day 9, followed by intraperitoneal glucose injection with a 25% glucose solution (1 mg/g body weight), and tail blood glucose levels were taken at 30, 60, 90, and 120 min; (D) For the ITT, mice began fasting at 9 AM on day 12 for 4 h, weighed and basal blood samples taken from the tail tip at 1 PM, followed by intraperitoneal human insulin injection (Novo Nordisk) (0.75mU/g body weight), and tail blood glucose levels taken at 15, 30, 45, and 60 min. (E) random plasma glucose of DEX- and Vehicle-treated mice after 14 days of injection (n = 7 per group); (F) ORO staining of liver prior and after DEX treatment, Scale bars, 50 μm and 20 μm. Values are expressed as the mean ± SD. *P < .05; **P < .01; ***P < .001
3.4 | DEX impedes SCD1 gene expression through suppressing α2A-AR via negative feedback

The expression of α2A-AR was detected in HepG2 cells and primary hepatocytes, it turns out that the expression of α2A-AR was first increased and subsequently a negative feedback loop to decrease gradually in a time-dependent manner across DEX treatment (Figure 4A and B). The results show that the negative feedback loop to inhibit α2A-AR after treating with DEX may be the critical factor for the suppression of SCD1 in liver.

Besides, as a rate-limiting enzyme that catalyzes the synthesis of monounsaturated fatty acids, SCD1 could also be regulated by many factors in liver, including dietary, and hormonal factors. Studies have revealed that insulin up-regulate SCD1 expression through PI3K and
mTOR pathways, another report showed that DEX can reduce insulin release through $\alpha_2A$-AR as well. Hence, we sought to identify whether DEX could regulate plasma insulin release and then influence the expression of SCD1. The level of plasma insulin in DEX group was indeed decreased 2 h after injection (Figure 4C) while increased after 24 h treatment (Figure 4D), and this phenomenon was positive correlation with the changes in plasma glucose (Figure 4E) and $\alpha_2A$-AR expression. Thus, these results further suggest that treatment with DEX decrease the expression of SCD1 probably through suppressing $\alpha_2A$-AR via negative feedback.

3.5 | DEX also protects mice against HFD-Induced inflammation

To investigate the effects of DEX on HFD-induced inflammation, several key molecules closely related with inflammation in MAPK and NFκB signaling pathways were detected. We found that the phosphorylation of important events, JNK, P38, and P65 were significantly decreased in liver with DEX treatment (Figure 5A-D). These data all suggest that DEX may improve HFD-induced inflammation by inhibiting the MAPK/NFκB signaling pathway in vivo.

4 | DISCUSSION

NAFLD usually begins with an aberrant triglyceride (TG) and T-CHO accumulation in hepatocytes due to metabolic imbalances such as increased de novo lipogenesis. High levels of plasma TG, T-CHO, and saturated fatty acids contribute to metabolic syndrome-associated inflammation and the secretion of pro-inflammatory cytokines. It has been reported that DEX had protective effects in the hippocampus, spinal cord, heart, liver, and kidney to the sympathetic system. In the central nervous system, $\alpha_2A$-ARs are predominantly located presynaptically and modulate the release of

[Figure 5: DEX protects mice against HFD-induced inflammation. (A, B and C) Western blot analysis of p-JNK, p-P38, p-P65 and JNK, P38, P65 in liver from DEX- or Vehicle-treated mice respectively (n = 6 per group); (D) Quantitative analysis of the ratio of p-JNK, p-P38, and p-P65 compared to JNK, P38 and P65 in liver from DEX- and Vehicle-treated mice (n = 6 per group). Data were analyzed by unpaired two-tailed Student’s t-test. Values are expressed as the mean ± SD. *P < .05; ** P < .01; *** P < .001]
catecholamines through a negative feedback mechanism. Notably, nor-adrenaline was found to induce hepatocellular dysfunction and modulate the responsiveness of macrophages to pro-inflammatory mediators through the activation of the α2-AR. On the other hand, epinephrine impairs glucose tolerance by inhibiting insulin secretion and augmenting hepatic glucose output via stimulation of both gluconeogenesis and glycogenolysis. In our study, we found that DEX treatment activates the α2A-AR, and subsequently a negative feedback loop to represents transient high plasma glucose while the levels of plasma insulin decreased and then increased 24 h after DEX injection. The decreased level of SCD1 in DEX-treated mice may attribute to the suppression of C/EBP, PPAR γ, and C/EBP α and act as a systemic effect. The intracellular concentration of SCD1 fluctuates in a wide range in response to complex and often competing hormonal and nutritional factors, such as insulin, leptin, and growth hormone as well. Insulin is a powerful activator of SCD1 transcription and has been shown to induce SCD1 expression. In this study, the suppression of SCD1 probably partly ascribe to the reduction in plasma insulin levels in plasma.

Studies have shown that DEX regulates inflammation through activate or deactivate ERK, JNK, and P38 MAPK pathways. Our results showed that treatment with DEX significantly decreased the phosphorylation of JNK, P38, and P65 in liver. These results suggest that treatment with DEX decreased the expression of SCD1 and improved inflammatory state probably through MAPK and NFκB signaling pathways.

In summary, our results showed that DEX could improve HFD-induced NAFLD, and the suppression of lipid accumulation was associated with down regulation of SCD1 in liver. The mechanism in regulating lipid metabolism, insulin sensitivity, and inflammation may due to suppressing the expression of C/EBP β, PPAR γ, and C/EBP α and a negative feedback loop to inhibit α2A-AR and the level of insulin in plasma through MAPK and NFκB singling pathway. DEX can be considered to be a potential adjuvant use for the treatment of NAFLD.

ACKNOWLEDGMENT

We thank Zhichun Zhang from the University of Duke-NUS Medical School for technical advice and guidance during the development of assays in this manuscript.

CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

AUTHORS' CONTRIBUTIONS

Tao made substantial contributions to perform experiments and analyze data. Guo, Xu, Wang, Xie, Chen, and Ma performed some experiments and analyzed some data. Tao and Li were involved mainly in drafting the manuscript and revising it critically for important intellectual content. Li gave final approval of the version to be published. Li contributed funding support.

FUNDING INFORMATION

This study was supported by National Key R&D Program of China [No. 2018YFA0800401 to X. Li]; Chongqing Science and Technology Foundation [No. cstc2018jcyJAX0232]; and Chongqing Education Foundation [KJZD-K201800402].

DATA AVAILABILITY STATEMENT

All data generated and analyzed in the study are available from the corresponding author upon reasonable request.

ORCID

Linfen Tao https://orcid.org/0000-0002-8926-6790
Xi Li https://orcid.org/0000-0002-2716-7308

REFERENCES

1. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69:2672-2682. https://doi.org/10.1002/hep.30251
2. Jennison E, Patel J, Scorletti E, Byrne CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019;95:314-322. https://doi.org/10.1136/postgradmedj-2018-136316
3. Ross AP, Darling JN, Parent MB. Excess intake of fat and sugar potentiates epinephrine-induced hyperglycemia in male rats. Diabetes Complications. 2015;29:329-337. https://doi.org/10.1016/j.dci.2014.12.017
4. Angulo P. Nonalcoholic fatty liver disease. New Engl J Med. 2002;346:1221-1231. https://doi.org/10.1056/NEJMra011175
5. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48(Suppl 1):5104-112. https://doi.org/10.1016/j.jhep.2008.01.009
6. Zhang X, Fan L, Wu J, et al. Macrophage p38alpha promotes nutritional steatohepatitis through M1 polarization. J Hepatol. 2019. https://doi.org/10.1016/j.jhep.2019.03.014
7. Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management. Endocr Rev. 2019. https://doi.org/10.1210/edrv/bnu009
8. Ghareghani P, Shanaki M, Ahmadi S, et al. Aerobic endurance training improves nonalcoholic fatty liver disease (NAFLD) features via miR-33 dependent autophagy induction in high fat diet fed mice. Obes Res Clin Pract. 2018;12:80-89. https://doi.org/10.1016/j.orec.2017.01.004
9. Keating SE, Hackett DA, Parker HM, et al. Effect of aerobic exercise training dose on liver fat and visceral adiposity. J Hepatol. 2015;63:174-182. https://doi.org/10.1016/j.jhep.2015.02.022
10. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology. 2012;55:1738-1745. https://doi.org/10.1002/hep.25548
11. Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019;40:1367-1393. https://doi.org/10.1210/er.2019-00034
12. Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019;70:711-724. https://doi.org/10.1002/hep.30429
13. Liu F, Zhu S, Ni L, Huang L, Wang K, Zhou Y. Dexmedetomidine alleviates insulin resistance in hepatocytes by reducing endoplasmic reticulum stress. Endocrine. 2019. https://doi.org/10.1007/s12020-019-02118-1
14. Sezer A, Memis D, Usta U, Sut N. The effect of dexmedetomidine on liver histopathology in a rat sepsis model: an experimental pilot...
15. Arslan M, Metin Comu F, Küçük A, Öztürk L, Yavak F. Dexmedetomidine protects against lipid peroxidation and erythrocyte deformability alterations in experimental hepatic ischemia reperfusion injury. Libyan J Med 2012; 7. https://doi.org/10.3402/ljm.v7i0.18185
16. Tüfek A, Tokgöz O, Aliosmanoğlu I, et al. The protective effects of dexmedetomidine on the liver and remote organs against hepatic ischemia reperfusion injury in rats. Int J Surg. 2013;11:96-100. https://doi.org/10.1016/j.ijsu.2012.12.003
17. Hui Yun S, Suk Choi Y. The Effects of Dexmedetomidine Administration on Postoperative Blood Glucose Levels in Diabetes Mellitus Patients Undergoing Spinal Anesthesia: A Pilot Study. Anesthesiology and pain medicine 6. (2016) e40483. https://doi.org/10.5812/aapm.40483
18. Coursin DB, Coursin DB, Maccioli GA. Dexmedetomidine. Anesthesiology and pain medicine 6. (2016) e40483. https://doi.org/10.1155/2014/905238
19. Madden CJ, Tupone D, Cano G, Morrison SF. α2 Adrenergic receptor-mediated inhibition of thermogenesis. J Neurosci. 2013;33:2017-2028. https://doi.org/10.1523/jneurosci.4701-12.2013
20. Wang Y, Wu S, Yu X, et al. Dexmedetomidine protects rat liver against ischemia-reperfusion injury partly by the alpha2A-Adrenoceptor Subtype and the Mechanism Is Associated with the TLR4/NF-kappaB Pathway. Int J Mol Sci. 2016;17: https://doi.org/10.3390/ijms17070995
21. Harding SD, Sharman JL, Faccenda e, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2019; updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. (2018); D1091-1106:46. https://doi.org/10.1093/nar/gkx1121
22. Alexander SPH, Christopoulos A, Davenport AP, et al. The Concise guide to pharmacology 2019:20: G protein-coupled receptors. Br J Pharmacol. 2019;176(Suppl 1):S21-s141. https://doi.org/10.1111/bph.14748
23. Lefevere P, Tripom E, Plumette C, Douaire M, Diot C. Effects of polyunsaturated fatty acids and clofibrate on chicken stearoyl-coA desaturase 1 gene expression. Biochem Biophys Res Commun. 2001;280:25-31. https://doi.org/10.1006.bbrc.2000.4070
24. Mauvoisin D, Rocque G, Arfa O, Radenne A, Boissier P, Mounier C. Role of the PI3-kinase/mTor pathway in the regulation of the stearoyl CoA desaturase (SCD1) gene expression by insulin in liver. J Cell Commun Signal. 2007;1:113-125. https://doi.org/10.1007/s12079-007-0011-1
25. Fagerholm V, Scheinin M, Haaparanta M. alpha2A-adrenoceptor antagonism increases insulin secretion and synergistically augments the insulinotropic effect of glibenclamide in mice. Br J Pharmacol. 2008;154:1287-1296. https://doi.org/10.1038/bjp.2008.186
26. Guo Y, Yu J, Wang C, et al. mir-212-5p suppresses lipid accumulation by targeting FAS and SCD1. J Mol Endocrinol. 2017;59:205-217. https://doi.org/10.1530/jme-16-0179
27. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 2009;48:1-26. https://doi.org/10.1016/j.plipres.2008.08.001
28. Zhang X, Shen J, Man K, et al. CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. J Hepatol. 2014;61:1365-1375. https://doi.org/10.1016/j.jhep.2014.07.006
29. Cheng X, Hu J, Wang Y, et al. Effects of Dexmedetomidine postconditioning on myocardial ischemia/reperfusion injury in diabetic rats: role of the PI3K/Akt-dependent signaling pathway. J Diabetes Res. 2018;2018:3071959. https://doi.org/10.1155/2018/3071959
30. Chen Z, Ding T, Ma CG. Dexmedetomidine (DEX) protects against hepatic ischemia/reperfusion (I/R) injury by suppressing inflammation and oxidative stress in NLRC5 deficient mice. Biochem Biophys Res Commun. 2017;493:1143-1150. https://doi.org/10.1016/j.bbrc.2017.08.017
31. Heinemann FS, Ozols J. Stearoyl-Coa desaturase, a short-lived protein of endoplasmic reticulum with multiple control mechanisms. Prostaglandins Leukot Essent Fatty Acids. 2003;68:123-133. https://doi.org/10.1016/s0952-3278(02)00262-4
32. Zhu X, Yan H, Xia M, et al. Metformin attenuates triglyceride accumulation in HepG2 cells through decreasing stearoyl-coenzyme A desaturase 1 expression. Lipids Health Dis. 2018;17:114. https://doi.org/10.1186/s12944-018-0762-0
33. Lounis MA, Escoula Q, Veillette C, Bergeron KF, Ntambi JM, Mounier C. SCD1 deficiency protects mice against ethanol-induced liver injury. Biochim Biophys Acta. 1861;2016:1662-1670. https://doi.org/10.1016/j.bbabio.2016.07.012
34. Frederico MJ, Vitto MF, Cesconetto PA, et al. Short-term inhibition of SREBP-1c expression reverses diet-induced non-alcoholic fatty liver disease in mice. Scand J Gastroenterol. 2011;46:1381-1388. https://doi.org/10.3109/00365521.2011.613945
35. Sampaio H, Ntambi JM. The role of stearoyl-CoA desaturase in obesity, insulin resistance, and inflammation. Ann NY Acad Sci. 2011;1243:47-53. https://doi.org/10.1111/j.1749-6632.2011.06303.x
36. Kurikawa N, Takagi T, Wakimoto S, et al. A novel inhibitor of stearoyl-CoA desaturase-1 attenuates hepatic lipid accumulation, liver
injury and inflammation in model of nonalcoholic steatohepatitis. *Biol Pharm Bull*. 2013;36:259-267. https://doi.org/10.1248/bpb.b12-00702

47. Sigala B, McKee C, Soeda J, et al. Sympathetic nervous system catecholamines and neuropeptide Y neurotransmitters are upregulated in human NAFLD and modulate the fibrogenic function of hepatic stellate cells. *PLoS One* 8. 2013:e72928. https://doi.org/10.1371/journal.pone.0072928

48. Moura E, Afonso J, Hein L, Vieira-Coelho MA. Alpha2-adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice. *Br J Pharmacol*. 2006;149:1049-1058. https://doi.org/10.1038/sj.bjp.0706950

49. Yang S, Zhou M, Chaudry IH, Wang P. Norepinephrine-induced hepatocellular dysfunction in early sepsis is mediated by activation of alpha2-adrenoceptors. *Am J Physiol Gastrointest Liver Physiol*. 2001;281:G1014-1021. https://doi.org/10.1152/ajpgi.2001.281.4.G1014

50. Shi Y, Shu ZJ, Xue X, Yeh CK, Katz MS, Kamat A. beta2-Adrenergic receptor ablation modulates hepatic lipid accumulation and glucose tolerance in aging mice. *Exp Gerontol*. 2016;78:32-38. https://doi.org/10.1016/j.exger.2016.03.005

51. Chen Y, Xu C, Yan T, Yu C, Li Y. omega-3 Fatty acids reverse lipotoxicity through induction of autophagy in nonalcoholic fatty liver disease. *Nutrition*. 2015;31:1423-1429 e1422. https://doi.org/10.1016/j.nut.2015.05.022

52. Mauvoisin D, Prevost M, Ducheix S, Arnaud MP, Mounier C. Key role of the ERK1/2 MAPK pathway in the transcriptional regulation of the Stearoyl-CoA Desaturase (SCD1) gene expression in response to leptin. *Mol Cell Endocrinol*. 2010;319:116-128. https://doi.org/10.1016/j.mce.2010.01.027

53. Zhang X, Wang J, Qian W, et al. Dexmedetomidine inhibits inducible nitric oxide synthase in lipopolysaccharide-stimulated microglia by suppression of extracellular signal-regulated kinase. *Neuro Res*. 2015;37:238-245. https://doi.org/10.1179/1743132814y.000000426

54. Liao Z, Cao D, Han X, et al. Both JNK and P38 MAPK pathways participate in the protection by dexmedetomidine against isoflurane-induced neuroapoptosis in the hippocampus of neonatal rats. *Brain Res Bull*. 2014;107:69-78. https://doi.org/10.1016/j.brainresbull.2014.07.001

---

**How to cite this article:** Tao L, Guo X, Xu M, et al. Dexmedetomidine ameliorates high-fat diet-induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice. *Pharmacol Res Perspect*. 2021;9:e00700. https://doi.org/10.1002/prp2.700